Oxybutyninum Aflofarm (Oxybutynin Hydrochloride)

Oxybutynin Hydrochloride, the active ingredient in Oxybutyninum Aflofarm, is an anticholinergic presented as a tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults. GNH USA supplies Oxybutyninum Aflofarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxybutyninum Aflofarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxybutyninum Aflofarm is an anticholinergic medication that reduces involuntary bladder contractions.

- Overactive bladder: Improves bladder capacity and reduces urgency episodes. - Urge urinary incontinence: Decreases the frequency of involuntary urine loss. - Detrusor overactivity associated with neurologic conditions: Helps control bladder spasms caused by neurological disease.

Oxybutyninum Aflofarm may produce a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Dry mouth - Constipation - Blurred vision - Drowsiness - Urinary retention - Headache

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Tachycardia or arrhythmia - Acute urinary retention requiring catheterisation - Hallucinations or severe confusion - Narrow‑angle glaucoma - Elevated liver enzymes

When prescribing Oxybutyninum Aflofarm, clinicians should consider several safety aspects.

- Assess renal and hepatic function: Adjustments may be needed in impairment. - Review cardiac history: Anticholinergic load can affect heart rate. - Evaluate for glaucoma: Risk of precipitating angle‑closure attacks. - Monitor for urinary retention: Especially in patients with prostate enlargement. - Caution in elderly patients: Higher susceptibility to cognitive effects. - Store at ambient temperature: Keep in original container, protect from moisture and light.

Oxybutyninum Aflofarm can interact with other medicines that influence anticholinergic burden or cardiac rhythm.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase oxy‑exposure. - Concurrent use with other anticholinergics (e.g., diphenhydramine) can amplify side‑effects. - QT‑prolonging agents (such ant  t  t  t  t  t  t  t)

Moderate   g   g   g  g  g  g  g

- Adjust dose when combined with CYP2D6 substrates. - Monitor electrolytes   t   t  t  t  t - Caution  t  t  t  t - Review renal function when used with diuret‑ - Assess for additive anticholinergic effects with tricyclic antidepressants.